GlassScriptPhysician profile
Patricia I Mutterer
NPI 1114933165
$18,480.70
in general payments reported to CMS, 2019-2025
15 companies · $5,382 in 2025
The $5,382 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,595 · 2022: $2,600 · 2023: $3,325 · 2024: $4,579 · 2025: $5,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,280.29 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,967.14 | 2021-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $2,538.79 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $2,261.80 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,042.03 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,936.12 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $1,927.16 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,162.91 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $591.53 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $479.72 | 2021-2022 | |
| Axsome Therapeutics, INC. | $426.60 | 2022-2025 | Auvelity |
| Lundbeck LLC | $379.18 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $316.76 | 2021-2025 | Fanapt |
| Indivior INC. | $302.74 | 2022-2024 | Perseris |
| Corium, LLC | $103.51 | 2022-2023 | Azstarys |
| Noven Therapeutics, LLC | $44.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Mutterer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.